Madam Speaker, I listened closely to what the member had to say. He spoke about transparency, and I could not agree more that we need transparency on what exactly we are signing on to as parliamentarians. When we talk about pharmaceuticals, 25% of the implementing legislation of the bill is to change the Patent Act in Canada. These will be the biggest changes to our Patent Act in over 20 years. It will result in Canadians paying more for medication for years to come.
We are being asked to approve these major changes, with the majority of the details only coming out later in the form of regulatory packages. The language in the act is a blank cheque regarding pharmaceutical costs for Canadians, and it is incomplete.
Is the member concerned that CETA will lead to increased costs of prescription drugs for Canadians, particularly as Canadians already pay more for prescription drugs than nearly every other OECD country?